Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow SUPN by emailGet an email when SUPN pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about SUPN, unsubscribe in one click. Privacy
📣 What SUPN Says Is Next
second half of 2026 · “The Company expects to initiate a Phase 1 single-ascending/multiple-ascending dose study in adult healthy volunteers in the second half of 2026.”
Company press release, Aug 3, 2026 · SEC filing
fourth quarter of 2026 · “The transaction is expected to close in the fourth quarter of 2026, subject to approval by stockholders of both companies, regulatory approvals and customary closing conditions.”
Company press release, Aug 3, 2026 · SEC filing
in 2026 · “The Company has selected ADHD as the lead indication for SPN-443 and expects to initiate a Phase 1 single-ascending/multiple-ascending dose study in adult healthy volunteers in 2026.”
Company press release, Nov 4, 2025 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full SUPN picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for SUPN and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.